241 related articles for article (PubMed ID: 18308565)
1. Design and synthesis of dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole oximes as potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases.
Dandu R; Zulli AL; Bacon ER; Underiner T; Robinson C; Chang H; Miknyoczki S; Grobelny J; Ruggeri BA; Yang S; Albom MS; Angeles TS; Aimone LD; Hudkins RL
Bioorg Med Chem Lett; 2008 Mar; 18(6):1916-21. PubMed ID: 18308565
[TBL] [Abstract][Full Text] [Related]
2. 8-THP-DHI analogs as potent Type I dual TIE-2/VEGF-R2 receptor tyrosine kinase inhibitors.
Hudkins RL; Zulli AL; Underiner TL; Angeles TS; Aimone LD; Meyer SL; Pauletti D; Chang H; Fedorov EV; Almo SC; Fedorov AA; Ruggeri BA
Bioorg Med Chem Lett; 2010 Jun; 20(11):3356-60. PubMed ID: 20430619
[TBL] [Abstract][Full Text] [Related]
3. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055.
Gingrich DE; Reddy DR; Iqbal MA; Singh J; Aimone LD; Angeles TS; Albom M; Yang S; Ator MA; Meyer SL; Robinson C; Ruggeri BA; Dionne CA; Vaught JL; Mallamo JP; Hudkins RL
J Med Chem; 2003 Dec; 46(25):5375-88. PubMed ID: 14640546
[TBL] [Abstract][Full Text] [Related]
4. TIE-2/VEGF-R2 SAR and in vitro activity of C3-acyl dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole analogs.
Underiner TL; Ruggeri B; Aimone L; Albom M; Angeles T; Chang H; Hudkins RL; Hunter K; Josef K; Robinson C; Weinberg L; Yang S; Zulli A
Bioorg Med Chem Lett; 2008 Apr; 18(7):2368-72. PubMed ID: 18343109
[TBL] [Abstract][Full Text] [Related]
5. Novel C-3 N-urea, amide, and carbamate dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole analogs as potent TIE-2 and VEGF-R2 dual inhibitors.
Becknell NC; Zulli AL; Angeles TS; Yang S; Albom MS; Aimone LD; Robinson C; Chang H; Hudkins RL
Bioorg Med Chem Lett; 2006 Oct; 16(20):5368-72. PubMed ID: 16890434
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors.
Potashman MH; Bready J; Coxon A; DeMelfi TM; DiPietro L; Doerr N; Elbaum D; Estrada J; Gallant P; Germain J; Gu Y; Harmange JC; Kaufman SA; Kendall R; Kim JL; Kumar GN; Long AM; Neervannan S; Patel VF; Polverino A; Rose P; Plas Sv; Whittington D; Zanon R; Zhao H
J Med Chem; 2007 Sep; 50(18):4351-73. PubMed ID: 17696416
[TBL] [Abstract][Full Text] [Related]
7. Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor.
Hodous BL; Geuns-Meyer SD; Hughes PE; Albrecht BK; Bellon S; Bready J; Caenepeel S; Cee VJ; Chaffee SC; Coxon A; Emery M; Fretland J; Gallant P; Gu Y; Hoffman D; Johnson RE; Kendall R; Kim JL; Long AM; Morrison M; Olivieri PR; Patel VF; Polverino A; Rose P; Tempest P; Wang L; Whittington DA; Zhao H
J Med Chem; 2007 Feb; 50(4):611-26. PubMed ID: 17253678
[TBL] [Abstract][Full Text] [Related]
8. Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas.
Kubo K; Shimizu T; Ohyama S; Murooka H; Iwai A; Nakamura K; Hasegawa K; Kobayashi Y; Takahashi N; Takahashi K; Kato S; Izawa T; Isoe T
J Med Chem; 2005 Mar; 48(5):1359-66. PubMed ID: 15743179
[TBL] [Abstract][Full Text] [Related]
9. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R
J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological study of 4-aminopyrimidine-5-carboxaldehyde oximes as antiproliferative VEGFR-2 inhibitors.
Huang S; Li R; Connolly PJ; Xu G; Gaul MD; Emanuel SL; Lamontagne KR; Greenberger LM
Bioorg Med Chem Lett; 2006 Dec; 16(23):6063-6. PubMed ID: 16979339
[TBL] [Abstract][Full Text] [Related]
11. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors.
Weiss MM; Harmange JC; Polverino AJ; Bauer D; Berry L; Berry V; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Whittington DA; Zanon R
J Med Chem; 2008 Mar; 51(6):1668-80. PubMed ID: 18324759
[TBL] [Abstract][Full Text] [Related]
13. Discovery of imidazole vinyl pyrimidines as a novel class of kinase inhibitors which inhibit Tie-2 and are orally bioavailable.
Buttar D; Edge M; Emery SC; Fitzek M; Forder C; Griffen A; Hayter B; Hayward CF; Hopcroft PJ; Luke RW; Page K; Stawpert J; Wright A
Bioorg Med Chem Lett; 2008 Aug; 18(16):4723-6. PubMed ID: 18676144
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): a novel oncology therapeutic agent.
Hudkins RL; Becknell NC; Zulli AL; Underiner TL; Angeles TS; Aimone LD; Albom MS; Chang H; Miknyoczki SJ; Hunter K; Jones-Bolin S; Zhao H; Bacon ER; Mallamo JP; Ator MA; Ruggeri BA
J Med Chem; 2012 Jan; 55(2):903-13. PubMed ID: 22148921
[TBL] [Abstract][Full Text] [Related]
15. Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors.
Miyazaki Y; Matsunaga S; Tang J; Maeda Y; Nakano M; Philippe RJ; Shibahara M; Liu W; Sato H; Wang L; Nolte RT
Bioorg Med Chem Lett; 2005 May; 15(9):2203-7. PubMed ID: 15837294
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
[TBL] [Abstract][Full Text] [Related]
17. Design and effective synthesis of novel templates, 3,7-diphenyl-4-amino-thieno and furo-[3,2-c]pyridines as protein kinase inhibitors and in vitro evaluation targeting angiogenetic kinases.
Miyazaki Y; Nakano M; Sato H; Truesdale AT; Stuart JD; Nartey EN; Hightower KE; Kane-Carson L
Bioorg Med Chem Lett; 2007 Jan; 17(1):250-4. PubMed ID: 17027260
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors.
Borzilleri RM; Zheng X; Qian L; Ellis C; Cai ZW; Wautlet BS; Mortillo S; Jeyaseelan R; Kukral DW; Fura A; Kamath A; Vyas V; Tokarski JS; Barrish JC; Hunt JT; Lombardo LJ; Fargnoli J; Bhide RS
J Med Chem; 2005 Jun; 48(12):3991-4008. PubMed ID: 15943473
[TBL] [Abstract][Full Text] [Related]
19. RO4383596, an orally active KDR, FGFR, and PDGFR inhibitor: synthesis and biological evaluation.
McDermott LA; Simcox M; Higgins B; Nevins T; Kolinsky K; Smith M; Yang H; Li JK; Chen Y; Ke J; Mallalieu N; Egan T; Kolis S; Railkar A; Gerber L; Luk KC
Bioorg Med Chem; 2005 Aug; 13(16):4835-41. PubMed ID: 15953730
[TBL] [Abstract][Full Text] [Related]
20. Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis.
La DS; Belzile J; Bready JV; Coxon A; DeMelfi T; Doerr N; Estrada J; Flynn JC; Flynn SR; Graceffa RF; Harriman SP; Larrow JF; Long AM; Martin MW; Morrison MJ; Patel VF; Roveto PM; Wang L; Weiss MM; Whittington DA; Teffera Y; Zhao Z; Polverino AJ; Harmange JC
J Med Chem; 2008 Mar; 51(6):1695-705. PubMed ID: 18311900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
